Archive: March 03 2021


Patient Power 1

CAR T-Cell Therapy Results in Remission for Myeloma Patients

  Mar 03 2021 Tagged CAR-T, MM

In a study posted online by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer.

Visit website